Literature DB >> 35536018

Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.

Joshua J Tu1, Amit Kumar1,2, Elena E Giorgi3, Joshua Eudailey4, Celia C LaBranche5, David R Martinez6, Genevieve G Fouda1,7,8, Yvetane Moreau9, Allison Thomas9, David Montefiori1,5, Feng Gao10,11, Manish Sagar9, Sallie R Permar1,4.   

Abstract

Despite the worldwide availability of antiretroviral therapy (ART), approximately 150,000 pediatric HIV infections continue to occur annually. ART can dramatically reduce HIV mother-to-child transmission (MTCT), but inconsistent drug access and adherence, as well as primary maternal HIV infection during pregnancy and lactation are major barriers to eliminating vertical HIV transmission. Thus, immunologic strategies to prevent MTCT, such as an HIV vaccine, will be required to attain an HIV-free generation. A primary goal of HIV vaccine research has been to elicit broadly neutralizing antibodies (bnAbs) given the ability of passive bnAb immunization to protect against sensitive strains, yet we previously observed that HIV-transmitting mothers have more plasma neutralization breadth than nontransmitting mothers. Additionally, we have identified infant transmitted/founder (T/F) viruses that escape maternal bnAb responses. In this study, we examine a cohort of postpartum HIV-transmitting women with neutralization breadth to determine if certain maternal bnAb specificities drive the selection of infant T/F viruses. Using HIV pseudoviruses that are resistant to neutralizing antibodies targeting common bnAb epitopes, we mapped the plasma bnAb specificities of this cohort. Significantly more transmitting women with plasma bnAb activity had a mappable plasma bnAb specificity (six of seven, or 85.7%) compared to that of nontransmitting women with plasma bnAb activity (7 of 21, or 33.3%, P = 0.029 by 2-sided Fisher exact test). Our study suggests that having multispecific broad activity and/or uncommon epitope-specific bnAbs in plasma may be associated with protection against the vertical HIV transmission in the setting of maternal bnAb responses. IMPORTANCE As mother to child transmission (MTCT) of HIV plays a major part in the persistence of the HIV/AIDS epidemic and bnAb-based passive and active vaccines are a primary strategy for HIV prevention, research in this field is of great importance. While previous MTCT research has investigated the neutralizing antibody activity of HIV-infected women, this is, to our knowledge, the largest study identifying differences in bnAb specificity of maternal plasma between transmitting and nontransmitting women. Here, we show that among HIV-infected women with broad and potent neutralization activity, more postpartum-transmitting women had a mappable plasma broadly neutralizing antibody (bnAb) specificity, compared to that of nontransmitting women, suggesting that the nontransmitting women more often have multispecific bnAb responses or bnAb responses that target uncommon epitopes. Such responses may be required for protection against vertical HIV transmission in the setting of maternal bnAb responses.

Entities:  

Keywords:  BnAbs; HIV; MTCT; infant; maternal; neutralizing antibodies; vaccines

Mesh:

Substances:

Year:  2022        PMID: 35536018      PMCID: PMC9175633          DOI: 10.1128/jvi.00231-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  63 in total

1.  Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Authors:  Xueling Wu; Tongqing Zhou; Jiang Zhu; Baoshan Zhang; Ivelin Georgiev; Charlene Wang; Xuejun Chen; Nancy S Longo; Mark Louder; Krisha McKee; Sijy O'Dell; Stephen Perfetto; Stephen D Schmidt; Wei Shi; Lan Wu; Yongping Yang; Zhi-Yong Yang; Zhongjia Yang; Zhenhai Zhang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Melissa Simek; Dennis R Burton; Wayne C Koff; Nicole A Doria-Rose; Mark Connors; James C Mullikin; Gary J Nabel; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

2.  Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Amarendra Pegu; Ivelin S Georgiev; Ming Zeng; M Gordon Joyce; Zhi-Yong Yang; Sung-Youl Ko; Xuejun Chen; Stephen D Schmidt; Ashley T Haase; John-Paul Todd; Saran Bao; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

3.  MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms.

Authors:  Sudhir Kumar; Glen Stecher; Michael Li; Christina Knyaz; Koichiro Tamura
Journal:  Mol Biol Evol       Date:  2018-06-01       Impact factor: 16.240

4.  Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Authors:  Ling Xu; Amarendra Pegu; Ercole Rao; Nicole Doria-Rose; Jochen Beninga; Krisha McKee; Dana M Lord; Ronnie R Wei; Gejing Deng; Mark Louder; Stephen D Schmidt; Zachary Mankoff; Lan Wu; Mangaiarkarasi Asokan; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Jochen Kruip; Rebecca Sendak; Young Do Kwon; Tongqing Zhou; Xuejun Chen; Robert T Bailer; Keyun Wang; Misook Choe; Lawrence J Tartaglia; Dan H Barouch; Sijy O'Dell; John-Paul Todd; Dennis R Burton; Mario Roederer; Mark Connors; Richard A Koup; Peter D Kwong; Zhi-Yong Yang; John R Mascola; Gary J Nabel
Journal:  Science       Date:  2017-09-20       Impact factor: 47.728

5.  Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.

Authors:  Adam S Dingens; Hugh K Haddox; Julie Overbaugh; Jesse D Bloom
Journal:  Cell Host Microbe       Date:  2017-06-01       Impact factor: 21.023

6.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

7.  Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission.

Authors:  N Ahmad; B M Baroudy; R C Baker; C Chappey
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.

Authors:  Amit Kumar; Elena E Giorgi; Joshua J Tu; David R Martinez; Joshua Eudailey; Michael Mengual; Manukumar Honnayakanahalli Marichannegowda; Russell Van Dyke; Feng Gao; Sallie R Permar
Journal:  PLoS Pathog       Date:  2021-04-02       Impact factor: 7.464

9.  Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants.

Authors:  Genevieve G Fouda; Tatenda Mahlokozera; Jesus F Salazar-Gonzalez; Maria G Salazar; Gerald Learn; Surender B Kumar; S Moses Dennison; Elizabeth Russell; Katherine Rizzolo; Frederick Jaeger; Fangping Cai; Nathan A Vandergrift; Feng Gao; Beatrice Hahn; George M Shaw; Christina Ochsenbauer; Ronald Swanstrom; Steve Meshnick; Victor Mwapasa; Linda Kalilani; Susan Fiscus; David Montefiori; Barton Haynes; Jesse Kwiek; S Munir Alam; Sallie R Permar
Journal:  Retrovirology       Date:  2013-01-10       Impact factor: 4.602

10.  Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1.

Authors:  Georgia D Tomaras; Sallie R Permar; Matthew Zirui Tay; Erika L Kunz; Aaron Deal; Lu Zhang; Kelly E Seaton; Wes Rountree; Joshua A Eudailey; Jack Heptinstall; Michael D McRaven; Edgar Matias; Erin McGuire; Nicole L Yates; Lautaro G Perez; David C Montefiori; R Glenn Overman; Thomas J Hope; Xiaoying Shen; Linda Kalilani; Genevieve G Fouda
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.